Tscan Therapeutics is trading at $0.21, up 11.85%, alongside a broad market rally and reported 2.05% biotech-sector strength. - No November 4 company-specific announcement explaining the move was identified; available investor-relations listings showed no release newer than October 6. - Coverage described sector-wide optimism about reduced near-term drug-pricing concerns after the midterm results. - The reported September reorganization is not evidence of a new November 4 catalyst.